Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Treasury Shares (2016 - 2025)

Ligand Pharmaceuticals' Treasury Shares history spans 4 years, with the latest figure at $42.3 million for Q4 2013.

  • For Q4 2013, Treasury Shares changed 0.0% year-over-year to $42.3 million; the TTM value through Dec 2013 reached $42.3 million, changed 0.0%, while the annual FY2013 figure was $42.3 million, 0.0% changed from the prior year.
  • Treasury Shares for Q4 2025 was $455547.0 at Ligand Pharmaceuticals, up from $102000.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $512361.0 in Q2 2024 and bottomed at $102000.0 in Q3 2025.
  • The 5-year median for Treasury Shares is $369442.0 (2023), against an average of $358657.4.
  • The largest annual shift saw Treasury Shares rose 0.13% in 2011 before it changed 0.0% in 2012.
  • A 4-year view of Treasury Shares shows it stood at $42.2 million in 2010, then increased by 0.13% to $42.3 million in 2011, then changed by 0.0% to $42.3 million in 2012, then changed by 0.0% to $42.3 million in 2013.
  • Per Business Quant, the three most recent readings for LGND's Treasury Shares are $42.3 million (Q4 2013), $42.3 million (Q3 2013), and $42.3 million (Q2 2013).